Applications of artificial intelligence in drug delivery and pharmaceutical development
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Abstract Drug delivery aims to potentiate the therapeutic effect of medicinal drugs by conferring augmented physicochemical features upon them, for example, by overcoming the inherent instability of biologics, which impairs their pharmacokinetics. Taking advantage of the interactions with nano- to micron-size biological components, drug delivery has become strongly associated with nanotechnological innovation. Today, drug delivery is rapidly expanding, surpassing the borders between pharmaceutical sciences, biosciences, and engineering. This unprecedented transformation has been prompted by the evolution of computational methods that enable nanosystems design, engineering, and manufacturing. Artificial intelligence (AI) is poised to advance the design, characterization, and manufacturing of drug delivery nanosystems. Further, the power of big data is becoming a relevant tool to accomplish reverse engineering and continuous optimization of these systems. In this chapter, the implementation of AI in the R&D and manufacturing of drug delivery systems is covered, focusing on pharmaceutical development and close-to-market applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
Planning chemical syntheses with deep neural networks and symbolic AI
Segler, M. H. S., Preuss, M., & Waller, M. P. (2018) · Nature · doi:10.1038/nature25978 · Cited by 1,847
Insoluble drug delivery strategies: review of recent advances and business prospects
Kalepu, S., & Nekkanti, V. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.07.003 · Cited by 1,410
Organs-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
The big picture on nanomedicine: the state of investigational and approved nanomedicine products
Etheridge, M. L., Campbell, S. A., Erdman, A. G., Haynes, C. L., Wolf, S. M., & McCullough, J. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2012.05.013 · Cited by 1,088
Artificial intelligence in drug development: Present status and future prospects
Mak, K.-K., & Pichika, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.014 · Cited by 1,018
Carlson, M. (2015) · Digital Journalism · doi:10.1080/21670811.2014.976412 · Cited by 542
Organ-, body-and disease-on-a-chip systems
Shuler, M. L. (2017) · Lab on a Chip · doi:10.1039/c7lc90068f · Cited by 54
Cited by
The role of artificial intelligence in business transformation: A case of pharmaceutical companies
Kulkov, I. (2021) · Technology in Society · doi:10.1016/j.techsoc.2021.101629 · Cited by 188
Next-generation business models for artificial intelligence start-ups in the healthcare industry
Kulkov, I. (2023) · International Journal of Entrepreneurial Behavior & Research · doi:10.1108/ijebr-04-2021-0304 · Cited by 97
Hasan, H. E., Jaber, D., Al Tabbah, S., Lawand, N., Habib, H. A., & Farahat, N. M. (2024) · PLOS ONE · doi:10.1371/journal.pone.0296884 · Cited by 76
Metadata
- Authors
- Colombo, S.
- Venue
- Artificial Intelligence in Healthcare
- Publisher
- Elsevier
- Published
- 2020
- Pages
- 85-116
- OpenAlex
- W3037705025
- Cited by
- 50
- References
- 8
- FWCI
- 6.55
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Applications of artificial intelligence in drug delivery and pharmaceutical development. https://app.cochat.ai/papers/10.1016/b978-0-12-818438-7.00004-6
- The paper
- Colombo, S. (2020). Applications of artificial intelligence in drug delivery and pharmaceutical development. Artificial Intelligence in Healthcare. https://doi.org/10.1016/b978-0-12-818438-7.00004-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.